Education of the XY Chromosome and its Impact on Women’s Agency and Experience of Domestic Violence

Last registered on April 12, 2022

Pre-Trial

Trial Information

General Information

Title
Education of the XY Chromosome and its Impact on Women’s Agency and Experience of Domestic Violence
RCT ID
AEARCTR-0009206
Initial registration date
April 10, 2022

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
April 12, 2022, 8:19 AM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Affiliation

Other Primary Investigator(s)

Additional Trial Information

Status
In development
Start date
2022-06-01
End date
2023-03-01
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
Given the social milieu of India, the preference for sons is evident through skewed sex ratios in favor of male children in both the urban and rural areas of the country. The women who fail to bear male children are often subjected to abuse and are misattributed the responsibility of bearing a son. This study shall use an intervention to educate individuals about this misattribution and observe whether it translates into lower levels of domestic violence inflicted on women. It is further expected to address gender norms and attitudes at large and give more bargaining power to women. The study will be conducted among different demographic groups in the city of Ahmedabad, Gujarat.
External Link(s)

Registration Citation

Citation
Vyas, Pallavi. 2022. "Education of the XY Chromosome and its Impact on Women’s Agency and Experience of Domestic Violence." AEA RCT Registry. April 12. https://doi.org/10.1257/rct.9206
Experimental Details

Interventions

Intervention(s)
Individuals will be shown an infomercial that will be in the form of entertainment education (“edutainment”). The taunting and aspiration for the lady to bear a son and possible physical abuse will be depicted. Half of treatment arm 1, will see a version where the protagonist is reminiscing a conversation with the doctor who explains information about the Y chromosome responsible for the male child. The second treatment arm will also see the same infomercial as the first treatment arm, but in addition they will receive a celebrity endorsement that will further reinforce the message conveyed by the doctor.
Intervention Start Date
2022-07-15
Intervention End Date
2022-12-15

Primary Outcomes

Primary Outcomes (end points)
Women’s agency over reproductive decisions; women’s acceptance/tolerance for violence in relation to bearing a son.
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
Voters will be chosen by polling station within each of the 16 constituent assemblies of Ahmedabad. The list of voters is published by the Election department. Each constituent assembly has between 188 and 368 polling stations. Furthermore, each polling station has a list of approximately 1,000 voters. Voters will be selected randomly from each of the constituent assemblies.
Experimental Design Details
Not available
Randomization Method
Randomly pick individuals from the list of voters for each constituent assembly.
Randomization Unit
Randomization at the level of an individual
Was the treatment clustered?
Yes

Experiment Characteristics

Sample size: planned number of clusters
16 constituent assemblies.
Sample size: planned number of observations
1400.
Sample size (or number of clusters) by treatment arms
700 in the Treatment Group and 700 in the Control Group.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
MDE = .15
IRB

Institutional Review Boards (IRBs)

IRB Name
Institute for Financial Management and Research
IRB Approval Date
2021-10-13
IRB Approval Number
IRB00007107